Cellectis SA (ADR) (CLLS) Stock Surges 18% – Why is this stock up so much?

Share
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  

Shares of Cellectis SA (ADR) (NASDAQ:CLLS) have jumped 18.25% to $23.00 in pre-market trading this morning, even though the company did not release any news. Specializing in creating T-cells which have memories that allow them to attack cancer cells, they are one of the several companies looking to cure cancer using this relatively new and innovative approach.

Some investors are speculating that perhaps Cellectis SA (ADR) (NASDAQ:CLLS) has suddenly become an attractive buyout option for other large pharmaceutical companies. However, like mentioned above, nothing has been announced as of yet. An 18.25% jump in the stock price however doesn’t seem to be based on technical factors alone though, so speculation continues this morning on what could be causing this move. Does someone know something that we don’t? Is a buyout offer on the table? Has there been an FDA approval which has not been formally announced? We are not sure, but we will certainly keep an eye on it as the day unfolds.

Earnings from Cellectis SA (ADR) (NASDAQ:CLLS) are expected to be reported tomorrow, and it could be a big day for investors. Some investors are speculating that today’s move to the upside is related to another company’s successful Phase 3 trial. Celator Pharmaceuticals just announced a positive Phase 3 trial for a drug called VYXEOS.

The stock increased 0.78% or $0.15 during the last trading session, hitting $19.45. About 8,605 shares traded hands. CLLS has declined 45.55% since July 10, 2015 and is downtrending. It has underperformed the S&P500 by 36.08%.

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The company has a market cap of $684.31 million. The Firm specializes in the research, development and commercialization of rational genome engineering technologies. It currently has negative earnings. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement.

#focuskw=’Cellectis SA (ADR) (NASDAQ:CLLS)’##metadesc=’Shares of Cellectis SA (ADR) (NASDAQ:CLLS) have jumped 18.25% to $23.00 in pre-market trading this morning, even though the company did not release any news. Specializing in creating T-cells which have memories that allow them to attack cancer cells, they are one of the several companies looking to cure cancer using this relatively new and innovative approach.

Some investors are speculating that perhaps Cellectis SA (ADR) (NASDAQ:CLLS) has suddenly become an attractive buyout option for other large pharmaceutical companies. However, like mentioned above, nothing has been announced as of yet. An 18.25% jump in the stock price however doesn’t seem to be based on technical factors alone though, so speculation continues this morning on what could be causing this move. Does someone know something that we don’t? Is a buyout offer on the table? Has there been an FDA approval which has not been formally announced? We are not sure, but we will certainly keep an eye on it as the day unfolds.

Earnings from Cellectis SA (ADR) (NASDAQ:CLLS) are expected to be reported tomorrow, and it could be a big day for investors. Some investors are speculating that today’s move to the upside is related to another company’s successful Phase 3 trial. Celator Pharmaceuticals just announced a positive Phase 3 trial for a drug called VYXEOS.

‘##metarobot=’index’##newskw=’Aurinia Pharmaceuticals Inc news,Aurinia Pharmaceuticals Inc – (NASDAQ:AUPH),NASDAQ:AUPH Analyst rating analysis,Stock Analysis,Outlook and potential,AUPH Price change and trend,AUPH stock update’##sitemap=’include’##skipsocial##stockticker=’NASDAQ:CLLS’#